RevBio® Receives First FDA Approval for a “Bone Glue” to Treat Extremity Fractures in a Clinical Trial
LOWELL, Mass.–(BUSINESS WIRE)–RevBio® announced today that TETRANITE, the company’s first of its kind regenerative “bone glue” has been approved for a 20-patient pilot study to measure the biomaterial’s safety and efficacy to treat complex, multi-fragmented wrist fractures including those that involve articular surfaces. Read More>>